Crucially, they also demonstrate that cancer-selective inhibition of the NF-κB survival pathway is possible and provide a promising therapy with no preclusive toxicity that could be of profound benefit for patients with this cancer and, potentially, others for which NF-κB promotes survival via GADD45β (Lam et al., 2005, Ngo et al., 2006, Tracey et al., 2005). This evidence concerns the gene NFKB1 and cancer.